Bristol-Myers Squibb: A Better Earnings Outlook, Stronger Momentum Heading Into 2025
…
57,880$
-0,60%
Echtzeit-Aktienkurs Bristol-Myers Squibb Co.
Bid:
Ask:
Nachrichten zur Bristol-Myers Squibb Co. Aktie
Bristol-Myers Squibb Company (BMY) Wells Fargo 2024 Healthcare Conference (Transcript)
…
Global Hematologic Malignancies Market Size To Worth USD 144.58 Billion By 2033 | CAGR Of 7.97%
The Global Hematologic Malignancies Market Size was Valued at USD 67.18 Billion in 2023 and the Worldwide Hematologic Malignancies Market…
Bristol-Myers Squibb Company (BMY) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
…
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High
Rebounding growth could make shares of this leading drugmaker a big winner.…
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High
…
How To Put $100 In Your Retirement Fund Each Month With Bristol-Myers Squibb Stock
…
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO By Reuters
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO…
Billion-dollar Deals in Radiopharmaceuticals Catch Investor Attention
Recent mergers and acquisitions and partnership deals in the medical industry are showing signs of increasing investor interest in the…
Where Will Bristol Myers Squibb Be in 5 Years?
The drugmaker will go through key changes by the end of the decade.…
Evotec: Diese Zahlung von Bristol Myers Squibb treibt die Aktie an
Evotec erhält 75 Millionen Dollar von Bristol Myers Squibb für Fortschritte in der Krebsforschung.…
Evotec erhält 75 Millionen Dollar Meilensteinzahlung von Bristol Myers Squibb
HAMBURG (dpa-AFX) - Evotec hat in seiner Partnerschaft mit dem US-Pharmaunternehmen Bristol-Myers Squibb Fortschritte erzielt und so Meilensteinzahlungen…
EQS-News: Evotec verkündet starke Fortschritte in strategischer Partnerschaft mit Bristol Myers Squibb im Bereich Protein Degradation (deutsch)
Evotec verkündet starke Fortschritte in strategischer Partnerschaft mit Bristol Myers Squibb im Bereich Protein Degradation^EQS-News: Evotec SE / Schlagwort(e): SonstigesEvotec…
EQS-News: Evotec verkündet Fortschritt in strategischer Neurologie-Partnerschaft mit Bristol Myers Squibb (deutsch)
Evotec verkündet Fortschritt in strategischer Neurologie-Partnerschaft mit Bristol Myers Squibb^EQS-News: Evotec SE / Schlagwort(e): SonstigesEvotec verkündet Fortschritt in strategischer Neurologie-Partnerschaft…
Bristol-Myers Squibb: A Potential Comeback In Healthcare
…
Albumin-gebundenes Paclitaxel von Kexing Biopharm erhält EU-Marktzulassung
Kexing Biopharm: Shenzhen, China (ots/PRNewswire) - Am 28. Juli 2024 gab Kexing Biopharm die Genehmigung der Europäischen Kommission für Apexelsin®…
Analyst Report: Bristol-Myers Squibb Co.
…
Is Bristol Myers Squibb a Good Dividend Stock to Buy Now? @themotleyfool #stocks $BMY $PFE
A lowered outlook for 2024 and upcoming patent expirations have investors concerned about this pharmaceutical giants dividend program.…
Is Bristol Myers Squibb a Good Dividend Stock to Buy Now?
A lowered outlook for 2024 and upcoming patent expirations have investors concerned about this pharmaceutical giants dividend program.…
Bristol-Myers Squibb Earnings Reinforces Our Thesis
…
Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point
…
Why Bristol Myers Squibb Jumped Nearly 10% on Friday @themotleyfool #stocks $BMY
The pharmaceutical company is faring far better than most investors were anticipating at this point.…
Why Bristol Myers Squibb Jumped Nearly 10% on Friday
The pharmaceutical company is faring far better than most investors were anticipating at this point.…
Why Bristol Myers Squibb Jumped Nearly 10% on Friday
…
Bristol Myers Squibb (BMY) Q2 2024 Earnings Call Transcript
BMY earnings call for the period ending June 30, 2024.…
Bristol Myers Squibb Witnesses Strong Demand For Newer Drugs As Q2 Earnings Beat Expectations, Raises 2024 Profit Forecast
…
Bristol-Myers Squibb stock gains after raising full-year guidance By Investing.com
Bristol-Myers Squibb stock gains after raising full-year guidance…
Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs
The results come as Bristol Myers moves to cut $1.5 billion in costs by 2025 and reinvest that money into…
June PCE, Bristol Myers Squibb earnings: What to watch Friday
Asking for a Trend Host Josh Lipton breaks down what to watch on Friday, July 26th. Personal Consumption Expenditures (PCE)…
Global Musculoskeletal Market Size is Expected To Hold a Significant Share By 2033 | CAGR of 6.2%
The Market Size is Growing at a Substantial CAGR of 6.2% from 2023 to 2033 and the Worldwide Musculoskeletal Market…
NCLA Asks Third Circuit to Rule Against HHS’s Coercive Medicare Drug Price ‘Negotiation’ Program
Bristol Myers Squibb Company, et al. v. Xavier Becerra, et al. Bristol Myers Squibb Company, et al. v. Xavier Becerra,…
Bristol-Myers Squibb - Investors Are Too Long-Term Focused (NYSE:BMY)
Bristol-Myers Squibb faces challenges with patent expirations, but has long-term shareholder return potential. Read why BMY stock is a good investment.…
Bristol-Myers Squibb Is A Bargain Now
…
Is Bristol-Myers Squibbs Rich Dividend Yield Worth The Patent Cliff Correction Risk?
…
Bristol-Myers Squibb: Seriously Undervalued And Poised For An Inflection
…
Erste Schätzungen: Bristol-Myers Squibb vermeldet Zahlen zum jüngsten Quartal
Bristol-Myers Squibb wird voraussichtlich am 26.07.2024 in der Finanzkonferenz die Quartalszahlen zum jüngsten Jahresviertel – Abschlussdatum 30.06.2024 – vorstellen.Die Schätzungen…
Bristol-Myers Squibb: Time To Double Down
…
Is Bristol Myers Squibb Stock a Buy? @themotleyfool #stocks $BMY
Does Bristol Myers have the potential to be a market-beating stock?…
Is Bristol Myers Squibb Stock a Buy?
Does Bristol Myers have the potential to be a market-beating stock?…
Global Lenalidomide Drug Market Size To Worth USD 21.47 Billion By 2033 | CAGR Of 5.69%
The Global Lenalidomide Drug Market Size was Valued at USD 12.34 Billion in 2023 and the Worldwide Lenalidomide Drug Market…
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
These two pharma stocks are beloved by income investors.…
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
…
OrganoClick appoints Carin Eklund as new CFO
OrganoClick has appointed Carin Eklund as the new CFO for the group. She will lead OrganoClicks finance and economics department…
Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%
The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size…
Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least (NYSE:BMY)
Bristol-Myers Squibb still elevated forward P/E indicates its unlikely to see an uptick anytime this year. Click here to read…
Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least
…
Evotec: Gute Nachrichten
Evotec verkündet einen Fortschritt in der Partnerschaft mit Bristol Myers Squibb.…
Evotec: Ein wichtiger Fortschritt innerhalb der Neurologie-Partnerschaft mit Bristol-Myers Squibb - Aktienanalyse
Kulmbach (www.aktiencheck.de) - Evotec-Aktienanalyse von "Der Aktionär":
Marion Schlegel vom Anlegermagazin "Der Aktionär" nimmt die Aktie der Evotec SE (ISIN: DE0005664809,…
EQS-News: Evotec gibt Fortschritt in Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt (deutsch)
Evotec gibt Fortschritt in Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt^EQS-News: Evotec SE / Schlagwort(e): SonstigesEvotec gibt Fortschritt in Neurologie-Partnerschaft mit…
Bristol-Myers Squibb: Could This Be A Value Trap? (Technical Analysis)
…